Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Great Place To Work
Both drugs : Share GLP-1 and glucagon receptor agonism, once-weekly subcutaneous dosing, similar GI side effect profiles, and investigational status
Individuals with GHD do not produce sufficient amounts of GH, which leads to growth failure in children and metabolic issues in adults
Tirzepatide is a dual GIP/GLP-1 receptor agonist marketed by Eli Lilly under the brand names Mounjaro (type 2 diabetes) and Zepbound (chronic weight management)
US$ 29.38
US$ 27.06
US$ 20.18
